Nordic Haemophilia Council's practical guidelines on diagnosis and management of von Willebrand Disease

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 5, 2011, Pages 495-502

  Lassila, Riitta ^a,g   Holme, Pål André ^b   Landorph, Andrea ^c   Petrini, Pia ^d   Onundarson, Páll T ^e   Hillarp, Andreas ^f  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c Rigshospitalet   (Denmark)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF ICELAND   (Iceland)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g Unit of Coagulation Disorders   (Finland)

Author keywords

Guidelines; Nordic Haemophilia Council; von Willebrand disease

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; C REACTIVE PROTEIN; DESMOPRESSIN; ORAL CONTRACEPTIVE AGENT; TRANEXAMIC ACID; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD CELL COUNT; DENMARK; DRUG EFFICACY; DRUG INDUCED HEADACHE; EXERCISE; FAMILY HISTORY; FATIGUE; FINLAND; FLUID RETENTION; FLUSHING; GASTROINTESTINAL HEMORRHAGE; HEMOPHILIA; HUMAN; HYPONATREMIA; HYPOTENSION; ICELAND; INFECTION; INTRAUTERINE CONTRACEPTIVE DEVICE; LABORATORY TEST; MEDICAL SOCIETY; MENORRHAGIA; MUCOSAL BLEEDING; NAUSEA; NORDIC HEMOPHILIA COUNCIL; NORWAY; ORAL CONTRACEPTION; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROTHROMBIN TIME; SEIZURE; SIDE EFFECT; STRESS; SWEDEN; TACHYCARDIA; TACHYPHYLAXIS; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; VON WILLEBRAND DISEASE;

DENMARK; FINLAND; GEOGRAPHY; HEMOPHILIA A; HUMANS; ICELAND; NORWAY; PRACTICE GUIDELINES AS TOPIC; SWEDEN; VON WILLEBRAND DISEASES;

EID: 81755171930     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1281034     Document Type: Article

References (33)

1. von Willebrand EA. Hereditär pseudohemofili. Finsk Lakaresallsk Handl 1926 68 87-112
2. Sadler JE, Budde U, Eikenboom JC et al, Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006 4 10 2103-2114 (Pubitemid 44403432)
3. Tosetto A, Rodeghiero F, Castaman G et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006 4 4 766-773
4. Bowman M, Mundell G, Grabell J et al. Generation and validation of the condensed MCMDM-1VWD bleeding questionnaire for von Willebrand disease. J Thromb Haemost 2008 6 12 2062-2066
5. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Haemophilia 2000 6 Suppl 1 60-67 (Pubitemid 30468295)
6. Berntorp E, Önundarson PT. Prevalence of von Willebrand disease in the Nordic region. Haematologica Rep 2005 1 4-6
7. Favaloro EJ. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost 2007 33 8 727-744 (Pubitemid 351158442)
8. Baronciani L, Federici AB, Cozzi G, Canciani MT, Mannucci PM. von Willebrand factor collagen binding assay in von Willebrand disease type 2A, 2B, and 2M. J Thromb Haemost 2006 4 9 2088-2090 (Pubitemid 44226803)
9. Goodeve A, Eikenboom J, Castaman G et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007 109 1 112-121 (Pubitemid 46053051)
10. Lethagen S, Hillarp A, Ekholm C, Mattson E, Halldén C, Friberg B. Distribution of von Willebrand factor levels in young women with and without bleeding symptoms: influence of ABO blood group and promoter haplotypes. Thromb Haemost 2008 99 6 1013-1018 (Pubitemid 351810482)
11. Onundarson PT, Gudmundsdottir BR, Arnfinnsdottir AV, Kjeld M, Olafsson O. von Willebrand factor does not vary during normal menstrual cycle. Thromb Haemost 2001 85 1 183-184 (Pubitemid 32050964)
12. Sadler JE, Rodeghiero F, ISTH SSC Subcommittee on von Willebrand Factor. Provisional criteria for the diagnosis of VWD type 1. J Thromb Haemost 2005 3 4 775-777 (Pubitemid 41647892)
13. Gudmundsdottir BR, Marder VJ, Onundarson PT. Risk of excessive bleeding associated with marginally low von Willebrand factor and mild platelet dysfunction. J Thromb Haemost 2007 5 2 274-281 (Pubitemid 46139451)
14. Eikenboom J, Van Marion V, Putter H et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost 2006 4 4 774-782
15. Sadler JE. Low von Willebrand factor: sometimes a risk factor and sometimes a disease. Hematology Am Soc Hematol Educ Program 2009 106-112
16. Favaloro EJ. Toward a new paradigm for the identification and functional characterization of von Willebrand disease. Semin Thromb Hemost 2009 35 1 60-75
17. Holmberg L, Dent JA, Schneppenheim R, Budde U, Ware J, Ruggeri ZM. von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure. J Clin Invest 1993 91 5 2169-2177 (Pubitemid 23141493)
18. Schneppenheim R, Federici AB, Budde U et al. von Willebrand disease type 2M Vicenza in Italian and German patients: identification of the first candidate mutation (G3864A; R1205H) in 8 families. Thromb Haemost 2000 83 1 136-140 (Pubitemid 30045489)
19. Mazurier C, Goudemand J, Hilbert L, Caron C, Fressinaud E, Meyer D. Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Pract Res Clin Haematol 2001 14 2 337-347 (Pubitemid 32677083)
20. Casonato A, Pontara E, Sartorello F et al. Identifying carriers of type 2N von Willebrand disease: procedures and significance. Clin Appl Thromb Hemost 2007 13 2 194-200 (Pubitemid 46548371)
21. Eikenboom JC. Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. Best Pract Res Clin Haematol 2001 14 2 365-379 (Pubitemid 32677085)
22. Castaman G, Rodeghiero F, Tosetto A et al. Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2006 4 10 2164-2169 (Pubitemid 44400291)
23. Favaloro EJ, Patterson D, Denholm A et al. Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis. Br J Haematol 2007 139 4 623-626 (Pubitemid 350043816)
24. Franchini M, Lippi G. Acquired von Willebrand syndrome: an update. Am J Hematol 2007 82 5 368-375 (Pubitemid 46651140)
25. Federici AB, Budde U, Rand JH. Acquired von Willebrand syndrome 2004: International Registrydiagnosis and management from online to bedside. Hamostaseologie 2004 24 1 50-55 (Pubitemid 38233047)
26. Lethagen S, Harris AS, Sjörin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost 1987 58 4 1033-1036
27. Lethagen S, Ragnarson Tennvall G. Self-treatment with desmopressin intranasal spray in patients with bleeding disorders: effect on bleeding symptoms and socioeconomic factors. Ann Hematol 1993 66 5 257-260 (Pubitemid 23179050)
28. Castaman G, Lethagen S, Federici AB et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood 2008 111 7 3531-3539
29. Smith TJ, Gill JC, Ambruso DR, Hathaway WE. Hyponatremia and seizures in young children given DDAVP. Am J Hematol 1989 31 3 199-202 (Pubitemid 19198976)
30. Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM, HAEMATE P Surgical Study Group. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost 2007 5 7 1420-1430 (Pubitemid 46965370)
31. Warkentin TE, Moore JC, Anand SS, Lonn EM, Morgan DG. Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome. Transfus Med Rev 2003 17 4 272-286 (Pubitemid 37310934)
32. Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005 16 Suppl 1 S23-S26 (Pubitemid 40756405)
33. Sucker C, Scharf RE, Zotz RB. Use of recombinant factor VIIa in inherited and acquired von Willebrand disease. Clin Appl Thromb Hemost 2009 15 1 27-31